90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis6-month overall survival rate was 86%; follow-up continues and survival data continue to matureVerastem Oncology (NASDAQ: VSTM), a

90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis

6-month overall survival rate was 86%; follow-up continues and survival data continue to mature

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).

KRAS is mutated in more than 90% of pancreatic cancers, making it a key driver of tumor growth. The RAMP 205 trial was designed to evaluate whether simultaneous inhibition of KRAS-driven signaling and FAK-mediated resistance pathways, in combination with standard-of-care chemotherapy, could improve outcomes for patients living with metastatic pancreatic cancer.